

Index

A

3-ABA 146-149
5-aza-2'-deoxycytidine 37, 129, 198, 205-207
5-azacytidine (5-aza-C) 37, 81, 179, 191, 192, 198, 205, 208
Adenoma 59-61, 64-66, 90, 102, 118, 167, 189
ADP-ribose polymer 143-147, 149, 152
ALU sequence 51, 75
Androgen 42, 45
Anoikis 65
Anticancer target 171, 172
Antisense 7, 37, 128, 131, 159, 169-173, 177, 191-201, 213, 218, 224-226
Antisense oligonucleotide 131, 159, 169, 170, 172, 192, 198, 201, 213, 224
APC 46, 47, 59-62, 73, 77, 108, 128, 136, 189
Apoptosis 23, 44, 52, 59-62, 64, 65, 69-71, 81, 189, 195, 197, 198, 224
ARA70 45, 46
Atomic Force Microscopy (AFM) 148

B

Bcl-2 198, 224
BCR-ABL translocation 187
Biomarker 61, 69, 81, 112
Bladder cancer 42-44, 47-53, 157, 194
BMP-6 45, 46
Bona fide demethylase 160
BRCA1 69, 71, 73-76, 108, 189, 212
Breast 32-34, 36, 71, 73-75, 89, 98-101, 108, 112, 114, 118, 129, 157, 167, 168, 187, 189, 193, 212, 214

C

Cancer 5, 20, 25, 26, 31-37, 42-53, 59-66, 69-78, 80, 81, 85, 86, 88-90, 98, 102, 107-109, 112-115, 117-119, 121, 122, 125, 128-130, 132, 135, 137, 143, 150,

151, 156-158, 160-162, 165-168, 170-173, 178, 181, 183, 187-201, 205, 206, 210-214, 218, 219, 223-225, 230-233
Carcinogenesis 31, 32, 34-36, 44, 50, 61, 74, 75, 88, 90, 102, 117, 118, 142, 166, 167, 218, 224
Caveolin 45
CD44 46
CDKN1C 47
CDKN2A 44, 45, 46, 47, 50, 107, 108, 118
Cell cycle 1, 2, 5, 16, 20, 44, 45, 47, 50, 52, 61, 62, 6971, 73, 81, 125, 126, 129-137, 166, 171, 172, 194, 195, 197, 198, 208, 209, 211, 212, 232
Cell cycle kinetics 171, 172
Centromeric instability 6, 167, 191
Chemical carcinogen 42, 50, 166
Chemotherapy 32, 37, 42-44, 47, 52, 53, 112, 115, 157, 178, 182, 183, 197, 198, 200, 205, 209-214, 219, 224-226
ChIP 160, 162
Chip 48, 52, 64, 119, 122, 200, 201
Chromatin 4, 5, 13, 14, 19-26, 37, 44, 50, 51, 72, 74-76, 79, 81, 86, 87, 102, 107, 117, 126, 142, 143, 145, 146, 148, 149, 151, 152, 160-166, 187, 188, 192, 197, 199, 212, 230-232
Chromatin remodeling 5, 13, 14, 21, 24, 25, 26, 160, 197
Chronic myeloid leukemia (CML) 37, 108, 187, 189, 198, 213
Class prediction 120, 121
Clear-cell carcinoma 43
Colon 33, 34, 36, 48, 71, 73, 75, 90, 91, 93, 96, 97, 99, 118, 128, 168, 181, 187, 189, 190, 193-195, 213
Colon adenocarcinoma 34, 91, 93
CpG island 2, 7, 14, 32, 35, 36, 47, 48, 62, 69-81, 107, 109-115, 117-119, 126, 142, 143, 147-152, 162, 163, 188, 189
Cyclin D2 44

D

3-deaza 181, 182
DAD-R 44
DAPK (death associated kinase) 46, 47, 70, 71, 73, 81, 108, 198
DBCCR1 46, 47
De novo and maintenance methylation 25
Demethylase 3, 50, 126, 142, 143, 156, 158, 160-168, 170-173, 224, 231-233
Demethylating agent 66, 71, 81, 115, 167, 168, 170, 172, 188, 197, 198, 201, 232
Demethylation 2, 3, 7, 18, 31, 32, 37, 51, 66, 73, 74, 76, 129, 133, 143, 156, 158-166, 169-172, 188, 196-198, 200, 201, 208, 231, 232
Diagnosis 44, 46, 51, 52, 107, 108, 115, 121, 212, 230, 231, 233
Diet 42, 50, 129, 158, 166, 167, 188, 233
Differentiation 2, 3, 5, 22, 43, 44, 48, 64, 89, 93, 100, 118, 125, 126, 132-134, 136, 137, 159, 161, 168, 178, 180-183, 188, 191, 209, 213
Discovery technologies 119
Dysplastic carcinoma in situ 43
DNA delivery 219
DNA hypermethylation 6, 24, 31, 32, 34-36, 42, 44-53, 59, 62, 64, 65, 69-76, 78, 80, 81, 86, 101, 107, 108, 112-115, 117, 118, 121, 128-130, 132, 135, 142, 143, 146, 148-151, 156, 158, 162, 163, 165, 166, 168, 170, 172, 178, 187-190, 194, 212, 230-232
DNA hypomethylation 3, 6, 31-37, 45, 51, 52, 75, 76, 86, 91, 93, 102, 142, 157, 167, 168
DNA methylation 1-8, 13-16, 18-26, 31, 32, 34, 36, 37, 42, 44-53, 59, 62-66, 69-81, 85-91, 93, 94-102, 107-115, 117-122, 125, 126, 128-135, 137, 142, 143, 146-152, 156-172, 178, 179, 182, 183, 187-201, 205-210, 213, 214, 218, 224, 226, 230-233
DNA repair 1, 24, 59, 62-66, 69-71, 74, 81, 108, 145, 159

DNMT1 3-6, 13-25, 32, 50, 53, 74, 75, 118, 125-137, 149-152, 156, 158, 162, 167-172, 190-201, 232
DNMT3a 2, 5, 14, 16-19, 21-23, 50, 75, 125-127, 130, 135-137, 190-193, 197
DNMT3b 2, 6, 7, 14, 16-19, 21-23, 50, 51, 74, 75, 125-127, 130, 135, 136, 162, 167, 168, 190-193, 197
Drug delivery 218, 219
Drug resistance 47, 157, 205, 208, 210, 212, 223

E

E-cadherin 45, 46, 108, 132, 162, 189
Electrotransfer 218-226
Embryogenesis 1-3, 13, 14, 125, 159, 190
Enzyme Inhibition 182
Epigenetics 69, 72, 73, 76, 143

F

FAP 59, 60
FAS death receptor 45

G

G/T mismatch repair 159
G1 phase 130, 208, 209, 214
GAP 128, 191
Gene activation 118, 127, 143, 157, 160
Gene expression 1, 2, 4, 8, 20, 31, 35, 49, 69, 76, 117, 118, 126, 128, 134, 137, 142, 149, 152, 157, 160, 161, 165, 178, 182, 187, 188, 191-193, 196-198, 213, 220, 222, 224, 230, 231
Gene therapy 212, 218, 220-226
Genomic imprinting 4, 5, 24, 44, 74, 187
Germ cell cancer (GCC) 44, 45, 49
Gleevec™ 187
Global hypomethylation 34-36, 42, 44, 45, 47-51, 53, 89, 90, 102, 156-160, 162, 163, 165-173, 207, 230, 231, 233
GSTP1 45-47, 52, 53, 69-71, 73-75, 108, 118, 119

H

H19 4, 7, 45-47
 H1e 151, 152
 H3K9 methylation 21, 163
 HCT116 colon cancer cell 190, 194
 HDAC inhibitor 5, 21, 26, 198
HERV-K 32, 51, 52
 Heterochromatin 5, 6, 16, 23, 24, 32, 33, 35, 36, 74, 86-88, 90
 High-throughput 109, 111, 115, 119, 122
 Histone deacetylase (HDAC) 5, 6, 19-26, 52, 70, 74, 76, 81, 126, 130, 161-165, 188, 192, 197, 198, 205, 212
 Histone H1 4, 146, 151
 Histone methylase (HMT) 6, 20, 26
 Histone methyltransferase (HMET) 26, 70, 161, 163, 188
 HMG 145
hMLH1 59, 60, 62, 63, 65, 69-71, 73-75, 107, 108, 118, 189, 195, 197
 HNPCC 60, 74
HPP1 62, 65
 Hyperplastic polyp 61, 62, 64, 65

I

ICF syndrome 33, 35, 51, 74, 167, 191
IGF2 4, 7, 45-47
 Imprinting pattern 45
 In vivo 2, 3, 6, 16, 19, 20, 32, 129, 142, 145-149, 151, 159, 164, 168, 172, 191, 195, 196, 206, 209, 211, 213, 218-220, 222-225
InHAT 163, 165
Inhibin α 45, 46
 Interacting factor 20
 Invasion 8, 45, 46, 108, 157, 166, 168-173

J

JAK/STAT 197

L

Leukemia 22, 34, 37, 74, 88, 107, 108, 120, 132, 157, 162, 167, 180-182, 187, 189, 196, 198, 205, 206, 208-211, 213, 214
LINE-1 32, 35, 36, 45, 46, 51, 135, 157
 Lung 16, 33, 34, 37, 73, 81, 87-89, 99, 107, 108, 118, 157, 158, 160, 167, 172, 187, 189, 193, 205, 206, 213, 225

M

MBD2 5, 19, 23, 76, 160, 161, 171-173, 218, 224-226, 232
Mbd2^{-/-} knock out mice 160, 172
 MBD2b 160
 MBD4 76, 159
 MCF-7 168
 MDA-MB-231 168
MDR1 47, 52, 157
 MeCP1 4, 5, 76, 160
 MeCP2 4, 5, 7, 20, 23, 74, 76, 80, 126, 143, 160, 163
 Metastatic breast cancer 157
 Metastatic tumor 34, 42
 Methylation analysis 16, 48, 52, 114, 117, 119, 197, 201
 Methylation chip 52, 200
 Methylation machinery 5, 13, 14, 42, 118, 134, 156, 158, 162, 172, 197, 218, 224, 226, 231, 232
 Methylation sensitive restriction enzyme 2, 87
 Methyl CG DNA glycosylase (5-MCDG) 159
 Methyl-deficient diet 158, 166
 Methylphosphonate 195, 196
 MG98 194, 195, 198-201
MGMT 62, 63, 65, 66, 69-71, 73, 74, 81, 107, 108, 122
 Microarray 50, 80, 107, 109, 112, 113, 115, 117, 119-122
 Microsatellite instability 60-62, 63, 74, 118
 Motility 157, 168, 171
MS-PCR 47, 52
MS-SNuPE 47, 78
MTHFR 50
MTS1 108, 157, 168, 170
MTS1/S100A4 157
 Myelodysplastic syndrome (MDS) 37, 198, 213
 MYOD1 188

N

NAD 143, 144, 179, 180
NEP 45, 46
 NIH/3T3 mouse fibroblast 146, 148
 Nonseminomas 44, 46, 48, 49, 53
 Nonviral 218, 223, 225
 N-terminal tails of histones 146
 Nuclear matrix protein 145, 147
 Nucleoside 86, 178-182, 188, 191, 192, 198, 213

O

2'-O-methyl 193, 196
 2'-O-propyl 196
 Oncogene 32, 33, 45, 47, 48, 51, 70, 73, 75,
 76, 85, 86, 117, 118, 133, 157, 166, 167,
 188, 189, 191, 196, 198

P

p16^{INK4A} 45, 47, 48, 52, 62, 69-71, 73, 76, 81,
 108, 189, 190, 194, 195
 p21 108, 130, 131, 134, 135, 147, 151, 214
 p53 44, 47, 53, 71, 73, 74, 118, 147
 Pancreatic ductal adenocarcinoma 157
 Passive demethylation 3, 159, 164, 169, 170
 PCNA 14, 19, 20, 126, 130, 131, 134-136,
 147, 150, 151, 166, 169, 190, 197
 Pericentromeric 16, 23, 33, 35, 74, 85, 157,
 167
 Pharmacology 205-208, 211-213
 Phase I clinical trials 198, 199, 209, 210
 Phase II clinical trials 52, 198, 199
 Phosphodiester backbone 195
 Phosphorothioate 193, 195, 196, 198
 PML-RAR 19, 22, 23, 74, 162, 196
 Poly(ADP-ribose) polymerase (PARP)
 142-146, 149-152
 Poly(ADP-ribosyl)ation 142, 143, 145-151
 Posttranscriptional 125, 126, 129-137
 Post-transplantation lymphomatous disease
 93, 94
 Prognosis 37, 44, 46, 48, 90, 108, 118, 197,
 198
 Prostate cancer 34, 36, 42, 43, 45, 48, 50-53,
 75, 118, 122, 157, 168
 Prostate intraepithelial neoplasia 45
 Prostate-specific antigen (PSA) 52, 119
 Protein-protein interaction 13, 16, 21, 22,
 126, 130, 166, 169, 170, 196, 197
 Purine 178, 180, 182

R

5' regulatory region 112, 188
RARB2 45-47, 69-71
 Ras mutation 48, 60-62, 128
RASSF1A 46, 47, 195
 Regulation 2, 4, 7, 13, 14, 19-21, 44-48, 61,
 74, 76, 107, 114, 125-137, 172, 178,
 187, 188, 196-199, 201, 222, 232, 233
 Renal cell carcinoma 32, 34, 42, 43, 49
 Restriction landmark genome scanning
 (RLGS) 35, 36, 48, 79, 119

S

S-adenosylhomocysteine (SAH) 50, 158,
 178-180, 233
 S-adenosylhomocysteine hydrolase (SAHase)
 178-182
 S-adenosylmethionine 50, 79, 87, 158, 179,
 190, 233
 S-adenosylmethionine (AdoMet) 125, 158,
 166, 167, 233
 S-adenosylmethionine (SAM) 50, 74, 79, 179,
 190
 Satellite 2 32, 157, 167, 191
 Screening 79, 107, 109, 119, 120, 122
 Seminomas 34, 44, 46, 48, 51
 Sensitive detection 118, 122
 Serrated adenoma 65, 66
 Serum DNA 80
 Signaling pathway 125, 127-129, 137, 196
SINE 51
 siRNA 169, 192-195, 197
 Solid carcinoma 43
 S phase 14, 20, 23, 62, 126, 129-133, 150,
 151, 166, 169, 205, 208-211, 213, 214
SUV39 161, 163

T

T24 cell line 53
Testes-specific 34
Testicular cancer 42, 44, 45, 51-53
Therapy 25, 37, 42, 44, 51, 52, 66, 81, 85, 86, 112, 156, 166, 170, 171, 196-201, 205, 206, 209, 211-214, 218, 220-226, 230-233
TIG1 45, 46
TNFRSF6 45, 46
Transcriptional 4, 5, 14, 15, 19-26, 48, 51, 69, 72, 74-76, 112, 118, 125, 126, 128-137, 148, 161, 166, 187, 188, 190, 191, 194, 195, 199, 222
Trichostatin A (TSA) 5, 21, 22, 162-165, 198, 212
Tumor classification 44, 109, 230
Tumor progression 31, 32, 35, 37, 42, 45, 48, 59, 86, 210, 233
Tumor staging 52, 108
Tumor suppressor gene 13, 14, 31, 42, 44-49, 62, 69-72, 7-76, 80, 81, 85, 101, 108, 117, 118, 126, 129, 130, 156, 162, 165, 166, 170, 172, 187-189, 191, 194-198, 200, 201, 208, 210, 212, 230
Tumor suppressor genes silencing 210
Tumorigenesis 14, 25, 26, 31, 35, 36, 70, 86, 101, 102, 107, 118, 142, 158-160, 165-168, 171, 172, 178, 188, 196, 205, 208, 211-213, 224, 226, 231, 232
Tyrosine kinase 187

U

Urokinase-type plasminogen activator (uPA) 114, 157, 168, 170
Urological cancer 42, 46-53

V

VHL 46, 47, 48, 53, 69, 70, 189

X

X-chromosome inactivation 4, 5, 21, 31, 187

Y

Y1 mouse adrenocortical tumor cells 191